E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary IgA nephropathy patients at risk of developing end stage renal disease |
Pazienti con nefropatia IgA primaria a rischio di sviluppare una malattia renale allo stadio terminale |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with kidney diseases that have damage to the kidneys associated with Immunoglobulin A |
Pazienti con malattie renali che hanno danni ai reni associato a immunoglobulina A |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069341 |
E.1.2 | Term | Berger's disease |
E.1.2 | System Organ Class | 100000004857 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To assess the effect of 9 months of retreatment with Nefecon on urine protein to creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) in patients who completed Study Nef 301 with Nefecon treatment; and •To assess the effect of 9 months of treatment with Nefecon on UPCR and eGFR in patients who completed Study Nef-301 with placebo treatment. |
•Valutare l'effetto di 9 mesi di ritrattamento con Nefecon sul rapporto proteine urinarie/creatinina (UPCR) e sulla velocità di filtrazione glomerulare stimata (eGFR) nei pazienti che hanno completato lo studio Nef 301 con il trattamento con Nefecon; e •Valutare l'effetto di 9 mesi di trattamento con Nefecon su UPCR e eGFR in pazienti che hanno completato lo studio Nef-301 con il trattamento con placebo. |
|
E.2.2 | Secondary objectives of the trial |
•To assess the safety and tolerability of 9 months of retreatment with Nefecon in patients who completed Study Nef-301 with Nefecon treatment; •To assess the safety and tolerability of 9 months of treatment with Nefecon in patients who completed Study Nef-301 with placebo treatment; •To assess the effect of 9 months of retreatment with Nefecon on additional aspects of renal function in patients who completed Study Nef-301 with Nefecon treatment; and •To assess the effect of 9 months of treatment with Nefecon on additional aspects of renal function in patients who completed Study Nef-301 with placebo treatment. |
•Valutare la sicurezza e la tollerabilità di 9 mesi di ritrattamento con Nefecon in pazienti che hanno completato lo studio Nef-301 con il trattamento con Nefecon; •Valutare la sicurezza e la rollerabilità di 9 mesi di trattamento con Nefecon in pazienti che hanno completato lo studio Nef-301 con il trattamento con il placebo; •Valutare gli effetti di 9 mesi di ritrattamento con Nefecon su ulteriori aspetti della funzione renale nei pazienti che hanno completato lo studio Nef-301 con il trattamento con Nefecon; e •Valutare gli effetti di 9 mesi di trattamento con Nefecon su ulteriori aspetti della funzione renale nei pazienti che hanno completato lo studio Nef-301 con il trattamento con placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Completed Study Nef-301, defined as Part A (9-month study drug treatment [Nefecon 16 mg/day or placebo] and 3-month follow-up) and Part B (12-month follow-up); -Completed Visit 17b in Study Nef-301 within 3 months before Study Visit 3; -On a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or maximum tolerated dose according to the 2012 KDIGO guidelines21 (see Appendix C). A stable dose is defined as a dose within 25% of the dose at Visit 17a or 17b in Study Nef 301; and -Proteinuria based on 2 consecutive measurements (24-hour urine sampling) after informed consent, separated by at least 2 weeks and calculated by the central laboratory. Both samples of the same parameter must show either of the following: oProteinuria >/=1 g/day (>/=1000 mg/day) in 2 consecutive measurements; or oUPCR >/=0.8 g/gram (>/=90 mg/mmol) in 2 consecutive measurements; and -eGFR >/=30 mL/min per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula confirmed by the central laboratory at Study Visit 1 or Study Visit 3. |
-Studio Nef-301 completato, definito come Parte A (trattamento farmacologico in studio di 9 mesi [Nefecon 16 mg/die o placebo] e follow-up di 3 mesi) e Parte B (follow-up di 12 mesi); -Visita 17b completata nello studio Nef-301 entro 3 mesi prima della Visita 3; -Su una dose stabile di terapia con inibitori della RAS (ACEIs e/o ARBs) alla dose massima consentita o alla dose massima tollerata in base alle linee guida 21 KDIGO del 2012 (vedere Appendice C). Una dose stabile è definita come una dose entro il 25% della dose alla Visita 17a o 17b nello studio Nef-301; e -Proteinuria basata su 2 misurazioni consecutive (prelievo di urina nelle 24 ore) dopo il consenso informato, separate da almeno 2 settimane e calcolate dal laboratorio centrale. Entrambi i campioni dello stesso parametro devono mostrare uno dei seguenti: oProteinuria >/=1 g/die (>/=1000 mg/die) in 2 misurazioni consecutive; o oUPCR >/=0.8 g/gram (>/=90 mg/mmol) in 2 misurazioni consecutive; e -eGFR >/=30 mL/min per 1.73 m2 utilizzando la formula Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) confermata dal laboratorio centrale alla Visita 1 o Visita 3 dello studio. |
|
E.4 | Principal exclusion criteria |
-Had a dose reduction to Nefecon 8 mg/day in Study Nef-301; -Systemic diseases that may cause mesangial IgA deposition including, but not limited to, Henoch Schönlein purpura, systemic lupus erythematosus, dermatitis herpetiformis, and ankylosing spondylitis; -Patients with nephrotic syndrome (i.e., proteinuria >3.5 g/day and with serum albumin <3.0 g/dL, with or without edema); -Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator. Patients with >/=140 mmHg systolic blood pressure or >/=90 mmHg diastolic blood pressure are not eligible. At least 1 blood pressure measurement at either Study Visit 1 or Study Visit 3 should be within these limits (based on up to 3 measurements, measured 1 minute apart, after resting in the supine position for at least 5 minutes); -Patients who have received rescue therapy with systemic immunosuppressants, including GCSs, during Study Nef-301; -Patients who have been treated with any systemic GCSs within the 3 months before screening; -Patients who have been treated with any systemic GCSs within the 12 months before screening except for a maximum of 3 periods of 2 weeks with the equivalent of 0.5 mg/kg/day prednisolone or less for non-IgAN indications; |
-Somministrazione di una dose ridotta a 8 mg/die di Nefecon nello studio Nef-301; -Malattie sistematiche che possono causare il deposito mesangiali inclusi, ma non limitati a, porpora Henoch Schönlein, lupus eritematoso sistematico, dermatite erpetiforme e spondilite anchilosante; -Pazienti con sindrome nefrosica (ad esempio proteinuria>3.5 g/die e con albumina sierica <3.0 g/dL, con o senza edema); -Pazienti con un controllo della pressione sanguigna inaccettabile definita come pressione sanguigna costantemente al di sopra delle linee guida nazionali per la malattia renale proteinurica, come valutato dallo Sperimentatore. I pazienti con pression sanguigna sistolica >/=140 mmHg o pressione sanguigna diastolica >/= 90 mmHg non sono eleggibili. Almeno 1 misurazione della pressione sanguigna alla Visita 1 o alla Visita 3 dello studio dovrebbe rientrare in questi limiti (sulla base di un massimo di 3 misurazioni, misurate a 1 minuto di distanza, dopo essere stati a riposo in posizione supina per almeno 5 minuti); -Pazienti che hanno ricevuto una terapia di emergenza con immunosoppressori sistematici, inclusi GCSs, durante lo studio Nef-301; -Pazienti che sono stati trattati con eventuali GCSs sistematici nei 3 mesi precedenti lo screening; -Pazienti che sono stati trattati con eventuali GCSs sistematici nei 12 mesi precedenti lo screening ad eccezione di un massimo di 3 periodi di 2 settimane con l'equivalente di 0.5 mg/kg/die di prednisolone o meno per indicazioni non-IgAN; |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Ratio of eGFR at 9 months compared to baseline, calculated using the CKD-EPI formula; and •Ratio of UPCR at 9 months compared to baseline. |
•Rapporto di eGFR al nono mese rispetto al basale, calcolato utilizzando la formula CKD-EPI; e •Rapporto di UPCR al nono mese rispetto al basale. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Included in E.5.1 |
Incluso in E.5.1 |
|
E.5.2 | Secondary end point(s) |
•Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline; •Short Form 36 quality of life assessment at 12 months compared to baseline; •Proportion of patients with microhematuria at 9 months compared to baseline; •Proportion of patients receiving rescue treatment and time to receiving rescue treatment; •Proportion of patients on dialysis, undergoing kidney transplantation, or with eGFR <15 mL/min per 1.73 m2; and •Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline. |
•Rapporto tra albumina urinaria e creatina (UACR) al 9° mese rispetto al basale; •Valutazione della qualità della vita Short Form 36 al 12° mese rispetto al basale; •Proporzione di pazienti con microematuria al 9° mese rispetto al basale; •Proporzione di pazienti che ricevono terapie di emergenza e tempi per ricevere trattamenti di emergenza; •Proporzione di pazienti in dialisi, sottoposti a trapianto di rene o con eGFR<15mL/min per 1.73 m2; e •Soppressione del cortisolo al mese 9 e 12, misurato come escrezione urinaria di cortisolo nell'arco di 24 ore rispetto al basale. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Included in E.5.2 |
Incluso in E.5.2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 66 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belarus |
Canada |
Korea, Republic of |
Taiwan |
Turkey |
United States |
Belgium |
Finland |
France |
Germany |
Greece |
Italy |
Poland |
Spain |
Sweden |
United Kingdom |
Czechia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |